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Abstract
Background: Robot-assisted radical prostatectomy (RARP) is performed by urologists as one of the surgical
procedures for treating prostate cancer. Numerous studies have been published with regard to the impact of
prostate weight on performing RARP but were limited by the insufficient number of patients and use of the
transperitoneal approach. This study aimed to determine the effect of prostate gland weight on the surgical and
short-term oncological outcomes of RARP using the extraperitoneal approach.
Methods: In total, 1168 patients who underwent extraperitoneal RARP (EP-RARP) performed by a single surgeon at
Yonsei University Severance Hospital between May 2009 and May 2016 were included in the study. The patients
were divided into 4 groups according to the prostate weight measured by transrectal ultrasonography
preoperatively. Intraoperative and postoperative outcomes were analyzed retrospectively. One-way analysis of
variance and the chi-square test were used in the statistical analyses.
Results: Age, the Gleason score, clinical stage, and pathological stage were significantly different. Patients with a
larger prostate size had a longer console time and higher estimated blood loss (P < 0.05). There were no significant
differences between the 4 groups in length of hospital stay, duration of catheterization, blood transfusion, body
mass index, prostate-specific antigen (PSA) level, history of abdominal surgery, intraoperative complications, positive
surgical margin, incidence of lymphocele, and PSA recurrence after 1 year.
Conclusions: The console time and estimated blood loss were significantly increased with a larger prostate size.
However, there were no significant differences in the oncologic outcome and intraoperative complications,
suggesting that EP-RARP requires meticulous bleeding control in patients with a prostate weighing > 75 g, and if
appropriate management is implemented for blood loss intraoperatively, EP-RARP can be performed regardless of
the prostate size.
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Background
Since Blinder and Kramer first performed robot-assisted
radical prostatectomy (RARP) in 2000, RARP has been
performed by numerous urologists as one of the surgical
procedures for treating prostate cancer (PCa) [1]. Several
studies comparing the operative outcomes of RARP with
those of open radical prostatectomy (ORP) have been
published and showed no significant differences in onco-
logic and functional outcomes, and better outcomes for
bleeding in RARP [2–4].
Among the several factors affecting radical prostatec-
tomy (RP), prostate weight has been reported by many
studies. According to the studies on the impact of pros-
tate weight on the operative outcomes of ORP, the larger
the prostate size, the greater the risk of blood loss and
blood transfusion, and the smaller the prostate size, the
greater is the incidence of a positive surgical margin [5].
In laparoscopic RP, similar to what is observed in ORP,
there is proportionate increase in the amount of bleed-
ing as the prostate enlarges in size, and the smaller the
prostate size, the higher the incidence of a positive
margin [6]. Numerous studies have been published on
the impact of prostate weight on RARP. However, there
were limitations to these studies in that the number of
patients was insufficient and most surgical methods were
performed using the transperitoneal approach [7–12].
Generally, the operative space is narrower in the extra-
peritoneal approach than in the transperitoneal ap-
proach. Thus, it may be more difficult to perform RP
using the extraperitoneal approach than to perform RP
using the transperitoneal approach in the case of a larger
prostate size.
Consequently, we aimed to determine whether the
prostate size affects perioperative or oncological out-
comes when the extraperitoneal approach is used. We
retrospectively analyzed 1168 patients who underwent
RARP using the extraperitoneal approach performed by
a single surgeon. In this paper, we evaluated the effect of
prostate gland weight on the surgical and short-term
oncological outcomes of RARP performed using the
extraperitoneal approach.
Methods
After institutional review board approval (approval num-
ber: YUHS 4–2018-0555) was obtained, we retrospect-
ively analyzed 1509 patients with PCa who underwent
extraperitoneal RARP (EP-RARP) performed by a single
surgeon in Yonsei University Severance Hospital be-
tween May 2009 and May 2016. In total, 1168 patients
were included after excluding patients with inadequate
medical records and suspected metastasis (clinical T4 or
M1) on preoperative magnetic resonance imaging (MRI)
of the prostate or whole body bone scan prior to surgery
for prostate cancer. The operator was an expert surgeon
who had previously performed 250 cases of RARP [13].
The patients were divided into 4 groups (group 1: < 25 g,
group 2: 25–50 g, group 3: 51–75 g, and group 4: > 75 g)
according to the prostate weight measured by transrectal
ultrasonography preoperatively. The prostate weight was
calculated using the following formula: height × length
× width × π/6. The clinical stage was classified according
to TNM staging, which was established by the American
Joint Committee on Cancer in 2010 using preoperative
pelvic magnetic resonance imaging and whole-body
bone scanning [14]. Transfusion records were included
in all cases intraoperatively and during hospitalization.
Prostate-specific antigen (PSA) recurrence was defined
as a continuous increase in the PSA level of 0.2 or more
after 1 year [15].
Operative technique
All RPs were performed using the extraperitoneal
approach with the da Vinci Surgical System (Intuitive
Surgical, Sunnyvale, CA, USA). The operation was per-
formed using the same procedure as previously reported
[16]. Six ports (4 robot arm ports and 2 assistant ports)
were used for RARP. A 1.5-cm vertical infraumbilical
incision was made, exposing the anterior rectus sheath.
The anterior rectus sheath was incised, and the rectus
abdominis muscle was swept. Then, an extraperitoneal
space was created using blunt finger dissection. A PDB
balloon dilator (Tyco, Princeton, NJ, USA) was used to
expand the extraperitoneal cavity. A 5-mm suction port
was inserted into the left upper side of the umbilicus
using the left index finger. A 12-mm camera port was
inserted into the infraumbilical incision site, and an
8-mm port was placed 8 cm away from the umbilicus in
both directions. A 12-mm assistant port was inserted 2
cm above the left anterior superior iliac spine, and an
8-mm port was inserted 2 cm above the right anterior
superior iliac spine. The endopelvic fascia was dissected.
The prostatic-vesical junction was identified, and the
proximal urethra was exposed. The vas deferens and
seminal vesicles were separated from Denonvilliers’
fascia. The dorsal vein complex was resected without
ligation, and the distal urethra was exposed. The pros-
tate apex was separated from the apical urethra and
Denonvilliers’ fascia. Both vascular pedicles were
resected, and the prostate was completely dissected with
the prostate specimen placed inside the entrapment bag
(Lap-bag, Sejong Med, Paju, Korea). Vesicourethral
anastomosis was performed using Monosyn 3–0 double
arm sutures (Aesculap, Center Valley, PA, USA). In a
posterior direction from the bladder, a continuous suture
was started 3 times on the right side and 3 times on the
left side. Then, an 18-French Foley catheter was inserted
into the bladder. Suturing was performed twice on both
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sides. After approximating the puboprostatic collar and
bladder, a knot was made.
Histopathological analysis of the specimens
All prostate specimens were processed in accordance
with a well-established protocol and reviewed by a path-
ologist [17]. The pathologist recorded the tumor location,
extracapsular extension (ECE), seminal vesicle invasion
(SVI), vas invasion, pathological Gleason score, patho-
logical stage, and positive surgical margin. A positive
surgical margin was defined as a cancer gland reaching
the inked margin.
Statistical analysis
Statistical analysis was performed using SPSS 23 soft-
ware (IBM Corp., Armonk, NY, USA). One-way analysis
of variance was used for normally distributed continuous
data. The chi-square test was used for categorical data.
Parameters with a P-value < 0.05 were considered statis-
tically significant.
Results
Of the 1168 patients, 157 were in group 1, 824 in group
2, 149 in group 3, and 38 in group 4. Patient characteris-
tics are shown in Table 1. The larger the prostate, the
older the patient’s age (P < 0.001). There were no signifi-
cant differences in history of abdominal surgery, body
mass index, and PSA level in terms of prostate weight.
The larger the prostate, the lower the Gleason score
(P < 0.05) and higher the incidence of clinical T1
stage cancer (P < 0.05).
Perioperative characteristics are presented in Table 2.
Length of hospital stay and duration of catheterization
were not correlated with prostate weight, and the inci-
dence of lymphocele was not significantly correlated
with prostate weight. The mean console time and mean
estimated blood loss were significantly increased with in-
creasing prostate weight (P < 0.001). Blood transfusion,
rectal injury, lymph node dissection, and nerve sparing
were not associated with prostate weight. There were no
other complications, except for rectal injury intraopera-
tively, and there were no open conversions.
Table 3 shows the pathologic outcomes. SVI and a
positive surgical margin were not significantly associated
with prostate weight. There was no significant difference
in PSA recurrence after 1 year in terms of prostate
weight. ECE significantly increased as the prostate
weight decreased (P < 0.05), and in the pathologic stage,
T2 increased as the prostate weight increased (P < 0.001).
Discussion
This study’s results showed that EP-RARP is as feasible
as transperitoneal RARP (TP-RARP) regardless of the
prostate weight. In our study, the greater the prostate
weight, the lower the Gleason score and lower the T
stage. This result is thought to be the effect of a lead
time bias, as described by Link et al. [7] Benign prostatic
hyperplasia (BPH) can lead to an increased PSA level, so
patients with BPH are more likely to be diagnosed at
a relatively early stage; in addition, prostate biopsy is
performed more often in patients with BPH than in
those without BPH [18]. In our study, ECE signifi-
cantly increased in patients with a lower prostate
Table 1 Patient characteristics classified according to the prostate weight
Prostate weight measured by TRUS (g) < 25 g 25–50 g 51–75 g > 75 g P-value
Patients (n) 157 824 149 38
Mean age (years) 64.1 ± 8.7 64.6 ± 7.4 65.9 ± 5.8 70.2 ± 5.4 < 0.001
Mean BMI (kg/m2) 23.8 ± 2.9 24.2 ± 2.6 25.1 ± 8.4 25.1 ± 3.4 0.07
Mean PSA level (ng/ml) 10.1 ± 9.5 10.5 ± 8.7 10.9 ± 8.6 15.9 ± 12.6 0.08
Prior abdominal surgery 29 (18.5%) 109 (13.2%) 26 (17.4%) 6 (15.8%) 0.55
Mean prostate weight by TRUS (g) 16.8 ± 2.9 31.0 ± 6.7 53.6 ± 6.7 92.1 ± 23.9 < 0.001
Mean pathologic prostate weight (g) 22.4 ± 5.2 35.4 ± 9.4 55.7 ± 10.1 81.2 ± 24.2 < 0.001
Preoperative Gleason score 0.03
2–6 57 (36.3%) 332 (40.3%) 80 (53.7%) 16 (42.1%)
7 62 (39.5%) 274 (33.3%) 43 (28.9%) 11 (28.9%)
8–10 38 (24.2%) 218 (26.5%) 26 (17.4%) 11 (28.9%)
Clinical stage 0.02
T1 35 (22.3%) 152 (18.4%) 43 (28.9%) 14 (36.8%)
T2 77 (49.0%) 430 (52.2%) 74 (49.7%) 14 (36.8%)
T3 45 (28.7%) 242 (29.4%) 32 (21.5%) 10 (26.3%)
TRUS transrectal ultrasonography, BMI body mass index, PSA prostate-specific antigen
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weight, and the T stage was increased more in pa-
tients with a low prostate weight than in those with a
high prostate weight. Our results are consistent with
those of previous studies. Briganti et al. [19] reported
that PCa in smaller glands is more aggressive and
therefore there are higher rates of ECE than when
PCa involves larger glands. Hong et al. [20] reported
that prostate size is not useful in predicting tumor
recurrence, but it is associated with the progression
of PCa. These explanations have not yet been clearly
elucidated. However, several hypotheses have been de-
veloped, including the following. First, men with a
small prostate secrete less testosterone. Low testoster-
one levels are associated with progressive PCa [21,
22]. Second, the benign tissues of BPH play an inhibi-
tory role in cancer cell progression [21, 23].
Table 2 Perioperative characteristics of patients classified according to the prostate weight
Prostate weight measured by TRUS (g) < 25 g 25–50 g 51–75 g > 75 g P-value
Patients (n) 157 824 149 38
Length of hospital stay (days) 5.5 ± 2.0 5.3 ± 2.0 5.1 ± 1.8 5.8 ± 2.9 0.30
Duration of catheterization (days) 11.0 ± 1.9 10.9 ± 2.0 11.1 ± 2.1 10.9 ± 1.8 0.49
Mean console time (min) 45.1 ± 14.8 47.0 ± 13.8 49.5 ± 14.1 61.7 ± 18.3 < 0.001
Mean estimated blood loss (ml) 347 ± 250 386 ± 262 456 ± 303 646 ± 423 < 0.001
Transfusion (n) 2 (1.3%) 2 (0.2%) 1 (0.7%) 1 (2.6%) 0.67
Rectal injury 1 (0.6%) 0 (0.0%) 2 (1.3%) 0 (0.0%) 0.44
Incidence of lymphocele 5 (3.2%) 31 (3.8%) 4 (2.7%) 2 (5.3%) 0.89
Lymph node dissection 0.88
No 115 (73.2%) 597 (72.5%) 114 (76.5%) 26 (68.4%)
Yes 42 (26.8%) 227 (27.5%) 35 (23.5%) 12 (31.6%)
Nerve sparing 0.89
None 8 (5.1%) 38 (4.6%) 5 (3.4%) 3 (7.9%)
Unilateral 2 (11.1%) 14 (1.7%) 2 (1.3%) 0 (0.0%)
Bilateral 147 (93.6%) 772 (93.7%) 142 (95.3%) 35 (92.1%)
TRUS, transrectal ultrasonography
Table 3 Pathologic outcomes of patients classified according to the prostate weight
Prostate weight measured by TRUS (g) < 25 g 25–50 g 51–75 g > 75 g P-value
Patients (n) 157 824 149 38
Extracapsular extension 0.003
Negative 87 (55.4%) 430 (52.2%) 104 (69.8%) 26 (68.4%)
Positive 70 (44.6%) 394 (47.8%) 45 (30.2%) 12 (31.6%)
Seminal vesicle invasion 0.88
Negative 146 (93.0%) 742 (90.0%) 143 (96.0%) 32 (84.2%)
Positive 11 (7.0%) 82 (10.0%) 6 (4.0%) 105 (9.0%)
Pathological Gleason score 0.01
3–6 35 (22.3%) 201 (24.4%) 62 (41.6%) 12 (31.6%)
7 86 (54.8%) 419 (50.8%) 57 (38.3%) 17 (44.7%)
8–10 36 (22.9%) 204 (24.8%) 30 (20.1%) 9 (23.7%)
Pathological stage 0.01
T2 85 (54.1%) 434 (52.7%) 103 (69.1%) 25 (65.8%)
T3 72 (45.9%) 379 (46.0%) 46 (30.9%) 12 (31.6%)
T4 0 (0.0%) 11 (1.3%) 0 (0.0%) 1 (2.6%)
Positive surgical margin 60 (38.2%) 351 (42.6%) 51 (34.2%) 10 (26.3%) 0.12
PSA recurrence (1 year) 16 (10.2%) 127 (15.4%) 14 (9.4%) 4 (10.5%) 0.65
TRUS transrectal ultrasonography
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In our study, there was no correlation between the pros-
tate size and a positive surgical margin in RARP. However,
Allaparthi et al. [8] and Link et al. [7] reported that the
lower the prostate weight, the more positive the surgical
margin is. This is because a small-sized prostate has a
higher cancer density than a large-sized prostate [24].
The mean console time and mean estimated blood loss
were significantly increased with increasing prostate
weight in our study. Boylu et al. [9] and Yasui et al. [10]
reported that the greater the prostate weight, the longer
the operative time, and Hirasawa et al. [11] reported that
the greater the prostate weight, the more the blood loss,
as it is thought that men with enlarged prostate glands
usually have more vascularity and broader resection
margins. However, the transfusion rate was not signifi-
cantly associated with the prostate weight, so even
though there is a greater amount of bleeding with a
greater prostate weight, it would not be clinically mean-
ingful. Surgeons feel technically challenged when operat-
ing on an enlarged prostate because BPH affects the
structure of the prostate in terms of its size and shape
[25]. As mentioned previously, the large amount of
bleeding and broad resection margin may have pro-
longed the console time.
Numerous studies have been published about the
impact of the prostate weight on performing RARP, but
the surgical technique most commonly used was the
transperitoneal approach. Most studies reported that
using the transperitoneal approach was feasible regard-
less of the prostate weight [7–12].
EP-RARP is associated with a lower incidence of bowel
injury and postoperative hernia compared to TP-RARP,
and there are no reports of symptoms of peritoneal
irritation caused by gas, urinary leakage, or bleeding.
However, there is a disadvantage in that the operative
space is narrow and accompanied by difficulty in obtain-
ing operative visibility [16, 26]. Because of these advan-
tages and disadvantages, we felt that it was necessary to
study the extraperitoneal approach.
According to previous studies conducted using the
extraperitoneal approach, Boczko et al. [27] reported that
blood loss is associated with a greater prostate weight.
Allaparthi et al. [8] reported that the prostate weight is
associated with a positive surgical margin. However, the
study by Boczko et al. has some limitations. In particular,
the statistical reliability of the data was not good, and the
effect of the small prostate was not determined because
the prostate weight was divided into only 2 categories
[27]. The study by Allaparthi et al. was limited in terms of
statistical reliability of the data because the numbers of
patients with a prostate weight < 30 g and > 80 g were
small [8]. In comparison, our study analyzed more pa-
tients than those of prior studies on the extraperitoneal
approach and had an increased power of data analysis.
There are some limitations to our study. First, the
number of patients was higher than that of prior studies,
but the number of patients with a prostate weight > 70 g
was relatively small compared to that in the other
groups. Second, the follow-up period was relatively short
(12 months), so the long-term evaluation of biochemical
recurrence was not possible. Third, as all procedures
were performed by a single expert surgeon, it was diffi-
cult to generalize the results. Finally, we did not perform
multiple linear regression analyses of factors associated
with operative outcomes. If we had performed it, we
would have been able to increase the validity of the study.
Conclusions
We found that the prostate size did not significantly
affect the oncologic outcomes or surgical complications
in performing EP-RARP. There was also no significant
difference in the length of hospital stay and duration of
catheterization. In this study, the size of the prostate was
correlated with the amount of estimated blood loss and
console time. However, there were no statistically signifi-
cant negative operative outcomes, such as transfusion,
longer hospitalization, longer catheterization, operative
complications, or oncologic outcomes due to increased
estimated blood loss. Therefore, we concluded that we
could perform EP-RARP safely regardless of the size of
the prostate.
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